By inhibiting glucose uptake of cancer cells, GLUT inhibitors lead to decreased NADPH production and increased NADP+/NADPH ratio, which in turn leads to abnormal formation of actin-cytoskeletal protein disulfide bond and collapse of F-actin network, ultimately promoting the occurrence of disulfidptosis [5]. The gene discussed is SLC2A1; the disease is cancer.